Phoenix Biotech Acquisition Stock Probability Of Bankruptcy
PBAXUDelisted Stock | USD 10.87 0.00 0.00% |
Phoenix |
Phoenix Biotech Acquisition Company probability of financial unrest Analysis
Phoenix Biotech's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Phoenix Biotech Probability Of Bankruptcy | Over 100% |
Most of Phoenix Biotech's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phoenix Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Phoenix Biotech probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Phoenix Biotech odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Phoenix Biotech Acquisition financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Phoenix Biotech Acquisition has a Probability Of Bankruptcy of 100%. This is 100.28% higher than that of the Capital Markets sector and significantly higher than that of the Financials industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Phoenix Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phoenix Biotech's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phoenix Biotech could also be used in its relative valuation, which is a method of valuing Phoenix Biotech by comparing valuation metrics of similar companies.Phoenix Biotech is currently under evaluation in probability of bankruptcy category among its peers.
Phoenix Fundamentals
Return On Asset | -0.0255 | |||
Current Valuation | 66.05 M | |||
Number Of Shares Shorted | 86 | |||
Net Income | (2.52 M) | |||
Cash And Equivalents | 553.77 K | |||
Cash Per Share | 0.02 X | |||
Total Debt | 650 K | |||
Current Ratio | 13.88 X | |||
Book Value Per Share | (2.20) X | |||
Cash Flow From Operations | (1.71 M) | |||
Short Ratio | 1.62 X | |||
Beta | 0.044 | |||
Total Asset | 42.37 M | |||
Retained Earnings | (10.76 M) | |||
Working Capital | 11.62 M | |||
Z Score | -0.03 | |||
Net Asset | 42.37 M |
About Phoenix Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phoenix Biotech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phoenix Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phoenix Biotech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
CEOs Directory Screen CEOs from public companies around the world | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |